Navigation Links
Case Western Reserve awarded $1.57M for corneal infection research
Date:10/7/2009

Researchers at Case Western Reserve University School of Medicine have been awarded a $1.57 million renewal grant from the National Eye Institute (NEI) of the National Institutes of Health to continue their study of corneal infections, specifically, bacterial keratitis, associated with contact lens wear. The grant will extend the work initiated last year with the receipt of a $2.4 million, five-year grant from the NEI.

The funding will support for four years the work of Eric Pearlman, Ph.D., professor and research director in the Department of Ophthalmology and Visual Sciences, as well as two postdoctoral investigators and one student working toward a Ph.D. The researchers hope to discover specific toll-like receptor (TLR) antagonists to regulate corneal inflammation, which could lead to the development of novel anti-inflammatory medications that could serve as alternatives to steroids to treat the infections.

Bacterial keratitis is a serious cause of visual impairment not only in the United States but also worldwide, and contact lens wear is a major risk factor for the infection in the cornea, the clear covering over the front part of the eye.

"Organisms can infiltrate an intact cornea of a lens-wearer, and a biofilm can form on the contact lens," Dr. Pearlman says. Although correctly performed cleaning of contact lenses can remove the biofilm, or aggregation of micro-organisms, he adds, "When one considers that 34 million people in the United States and about 140 million people worldwide wear contact lenses, even a low percentage of side effects translates into a large number of affected individuals."

The TLR family of pathogen recognition molecules plays a critical role in recognizing and responding to pathogens in the body, initiating anti-microbial inflammatory responses to them that often result in damage to tissue. In the absence of live bacteria, TLRs also respond to microbial products and can induce an inflammatory response in the cornea.

With the latest grant, the researchers will study the activation of TLR4, which is the major stimulatory component of Gram-negative bacteria, by large molecules called lipopolysaccharides, which elicit strong immune responses. They also will examine responses inside epithelial cells in the human cornea and in a murine model of corneal inflammation. The investigators' goal will be to identify potential areas on the cell surface and inside the cells that would be good targets for anti-inflammatory intervention.

Dr. Pearlman is the principal investigator leading a multidisciplinary team investigating fungal and bacterial keratitis that also includes Mahmoud A. Ghannoum, Ph.D., E.M.B.A., professor and director of the Center for Medical Mycology in the Department of Dermatology; Loretta B. Szczotka-Flynn, O.D., M.S., associate professor of ophthalmology and visual sciences; and Arne Rietsch, Ph.D., assistant professor of molecular biology and microbiology.

The Department of Ophthalmology and Visual Sciences is part of the Visual Sciences Research Center, which encompasses more than 40 vision researchers in 18 departments at Case Western Reserve University and University Hospitals Case Medical Center campus, including pharmacology, pathology, molecular biology, epidemiology and biostatistics, chemistry and biomedical engineering.


'/>"/>

Contact: Jessica Studeny
jessica.studeny@case.edu
216-368-4692
Case Western Reserve University
Source:Eurekalert

Related medicine news :

1. Director of UT Southwestern center honored with first international neurology medal
2. Dynatronics to Supply Western Rehabilitation Health Networks 114 Clinics
3. Northwestern Memorial HealthCare and Lake Forest Hospital Sign Affiliation Agreement
4. Motorolas 802.11n Wireless LAN Solution Improves Patient Care and Wireless Security at Memorial Medical Center of Western Michigan
5. Community Health Centers and Western Governors University Partner to Address RN Shortage
6. Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation
7. Join WQED Pittsburgh and The Press Club of Western Pennsylvania in Celebrating National Healthy Aging(R) Month and Kick Off Active Aging Week September 21-27
8. Catalyst Pharmaceutical Partners Licenses Exclusive Rights to New Class of GABA Aminotransferase Inhibitors From Northwestern University
9. UT Southwestern Responds to VA Announcement
10. Rabies Vaccination Program Underway in Western Pennsylvania
11. AHRF and Northwestern University to Present a Lecture on Hearing and Hearing Loss on August 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... staff members in 2017 who are passionate about making a difference in the ... and headquartered in Tampa, UMA, a nonprofit healthcare educational institution, has more than ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Sam & Associates ... to commercial and residential clients in the California Bay Area, is launching a charity ... in the region. , Heart disease is the primary killer of adult men and ...
(Date:1/19/2017)... ... January 19, 2017 , ... Tribble Insurance Agency, a ... eastern Virginia region, is inaugurating a charity event to honor Chad Phillip Dermyer, a ... duty last year, Chad Phillip Dermyer and his fellow officers were conducting routine stops ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... St. Catherine’s ... Center. , Siena Center is a skilled nursing facility on the grounds of the ... semiprivate rooms. It recently was voted the best nursing home in Mississippi for the ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... 2017 Spring Create Real Impact contest from Impact Teen Drivers and California Casualty. ... http://www.createrealimpact.com . , Educational grants totaling $15,000 will be awarded for the ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017  Abaxis, Inc. (NasdaqGS: ABAX ), ... and consumables for the medical and veterinary markets worldwide, ... results for the third quarter fiscal year 2017, ended ... p.m. ET on Thursday, January 26, 2017.  The Company ... year 2017 after the market closes on Thursday, January ...
(Date:1/19/2017)... -- Shire plc (LSE: SHP, NASDAQ: ... Drug Administration (FDA) has acknowledged receipt of the Class ... SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. SHP465 ... Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to provide ... designated Prescription Drug User Fee Act (PDUFA) action date. ...
(Date:1/19/2017)... January 19, 2017 While ... serious about reducing the FDA,s regulatory strictness as ... the medical drug industry, many of the leading ... clinical trials and development of advanced drug treatments ... with recent developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology: